JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on BioCryst Pharma (NASDAQ:BCRX) and increased the price target from $14 to $15.
May 07, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharma's price target was raised from $14 to $15 by JMP Securities, maintaining a Market Outperform rating.
The increase in price target by JMP Securities reflects a positive outlook on BioCryst Pharma, suggesting confidence in the company's future performance. This analyst endorsement is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100